MedTrace Logo

Allogeneic UCB Therapy With EPO in Children With CP

NCT01991145 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2020-01-18

No results posted yet for this study

Summary

This randomized controlled study aims to evaluate the efficacy and safety of allogeneic umbilical cord blood therapy combined with erythropoietin for children with cerebral palsy.

Conditions

  • Cerebral Palsy

Interventions

PROCEDURE

Umbilical Cord Blood therapy

HLA (Human Leukocyte Antigen) typing

BIOLOGICAL

Erythropoietin alfa

OTHER

Rehabilitation

Active rehabilitation

PROCEDURE

Placebo UCB

BIOLOGICAL

Placebo EPO

Sponsors & Collaborators

  • Ministry of Health & Welfare, Korea

    collaborator OTHER_GOV

  • LG Life Sciences

    collaborator INDUSTRY

  • Chong Kun Dang Pharmaceutical

    collaborator INDUSTRY

  • CHA University

    collaborator OTHER

  • MinYoung Kim, MD, PhD

    lead OTHER

Principal Investigators

  • MinYoung Kim, M.D., Ph.D. · CHA University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Months
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-26
Primary Completion
2017-06-24
Completion
2017-06-24

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01991145 on ClinicalTrials.gov